Entrectinib
| Use attributes for filter ! | |
| Molar mass | 560. 64 g/mol |
|---|---|
| Trade name | Rozlytrek |
| Other names | RXDX-101, NMS-E628 |
| Drug class | Antineoplastic agent |
| ATC code | WHO |
| License data | DailyMed |
| US | |
| FDA | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951343 |
About Entrectinib
Entrectinib is an anti-cancer drug used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It was approved in the United States on 15 August 2019.